Brian Duncan, MD: Brian is a Venture Partner for Arboretum Ventures and a pediatric cardiac surgeon who has more than 20 years of clinical experience. After completing training at Massachusetts General Hospital, he was a staff surgeon at Children’s Hospital in Boston, Seattle Children’s Hospital and Cleveland Clinic. Brian also has experience developing pediatric ventricular assist devices. Most recently, Brian was the Medical Director for Cleveland Clinic Emerging Businesses Unit. He has authored more than 100 peer-reviewed manuscripts, 25 book chapters, and the definitive textbook on pediatric circulatory support entitled Mechanical Support for Cardiac and Respiratory Failure in Pediatric Patients. He serves on the boards of BioOhio, American Society for Artificial Internal Organs and Accord Biomaterials. Brian received his B.S. and M.D. degrees from Indiana University and also has an M.B.A. from the University of Michigan.
Marc Galletti: Marc is a founder and Managing Director of Longitude Capital. He focuses on investments in medical devices and specialty pharmaceuticals, including drug-device combinations. From 2003 to 2006, Mr. Galletti was a Senior Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Mr. Galletti worked at Amerindo Investment Advisors and Vector Fund Management where prior venture capital investments included Align Technology (NASDAQ: ALGN), CancerVax (acquired by Micromet), Eyetech Pharmaceuticals (NASDAQ: OSIP) and Theravance (NASDAQ: THRX). Mr. Galletti has also worked in the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his life sciences industry career 16 years ago at APM, a management consultancy dedicated to improving operations performance within large acute-care hospitals. He currently serves on the Board of Velomedix and he has been a board member or board observer of Altiva Corporation, Aptus Endosystems, Broncus Technologies, Facet Solutions, MAP Pharmaceuticals (NASDAQ: MAPP), Sadra Medical, Sanarus Medical and Threshold Pharmaceuticals (NASDAQ: THLD). He also sits on the advisory boards for the Center of Biotechnology Management at the Kellogg School of Management and the Program for Biomedical Engineering at Brown University. Mr. Galletti holds an M.B.A. from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.
Steve Girouard, Ph.D: Steve is the Vice President, Emerging Technologies for the Corporate Office of Science and Technology at Johnson & Johnson. Based in Cleveland, Ohio, Steve is responsible for identifying emerging health care technologies and business opportunities in the Midwest. In this role, he works with faculty, researchers, entrepreneurs, technology incubators and early-stage investors to identify innovative products and business opportunities that may provide future growth across the Johnson & Johnson Family of Companies. Steve earned an undergraduate degree in Biomedical Engineering from Boston University and his Master’s and Doctoral degrees in Biomedical Engineering from Case Western Reserve University. Steve brings to COSAT a blend of experiences that includes academic research, venture capital investment, and corporate R&D. Steve started his career at Guidant Corporation in the Cardiac Rhythm Management division where he held various technology management positions. As Director of Basic Research at Guidant his responsibilities included the development of breakthrough cardiovascular technologies through a combination of internal and external research and development programs. Steve was recruited to the Cleveland Clinic to serve as the founding Executive Director of the Atrial Fibrillation Innovation Center, a center created for the development of novel technologies for the treatment of atrial fibrillation. Steve was previously a partner with Omega Funds and Oakwood Medical Investors where he focused on cardiovascular opportunities and medical devices. He holds over twenty patents and has authored numerous peer-reviewed articles and book chapters in the fields of cardiology and electrophysiology.
Read McCarty: Read has developed and marketed products for premature babies for more than 20 years. He was the founder and CEO of Hawaii Medical, acquired by Natus, (NASDAQ: BABY), and CEO and founder of Children’s Medical Ventures, acquired by Respironics (NASDAQ: RESP, now Phillips). Read's basic research includes work at Boston Children’s Hospital in blood separation technologies related to Thalassemia and other blood disorders. Currently, Read travels all over the US to meet with clinicians to discover needs and product improvements for the NICU.